# OnCo record paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019" ;
schema:name "Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)"@en ;
schema:description "Adding immunotherapy to chemotherapy for advanced small-cell lung cancer raised median survival from 10.3 to 13.0 months. Small, but it was the second positive first-line trial in the disease in thirty years."@en ;
schema:url ;
schema:dateModified "2026-09-25"^^xsd:date ;
schema:citation , , ;
onco:tag "lung-evidence" ;
schema:sameAs ;
schema:datePublished "2019"^^xsd:gYear ;
schema:author "Paz-Ares L, Dvorkin M, Chen Y, et al." ;
onco:related , , ;
onco:cancers , , ;
onco:sections ;
onco:technologies ;
onco:targets ;
onco:drugs , , , , , ;
onco:companies ;
onco:pathways ;
onco:terms , ;
onco:trials , ;
onco:people ;
onco:bottlenecks , , ;
onco:journals .